Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-5/BET-B: Lenzilumab + Remdesivir in Hospitalized COVID-19
NCT04583969Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of lenzilumab in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2020; status: completed.
02
Drugs
lenzilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04583969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583969.